Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

RRMM: Treatment Options in Early Relapse and in Triple-Class Refractory MM

July 21st 2022

Ajai Chari, MD provides an overview of treatment options in patients with multiple myeloma at first relapse and those with triple-refractory disease

Selecting Optimal Therapy in Transplant-Ineligible NDMM and Key Takeaways

July 21st 2022

Expert hematologist-oncologists home in on clinical trial data to consider which regimens are most appropriate for patients with transplant-ineligible NDMM.

Transplant-Ineligible NDMM: MAIA Study and SWOG-S0777 Studies

July 14th 2022

An overview of the frontline treatment armamentarium for patients with transplant-ineligible multiple myeloma and review of the MAIA and SWOG-S0777 trials.

Role of Maintenance Therapy and Key Takeaways in Transplant-Eligible NDMM

July 14th 2022

Before closing out their discussion on transplant-eligible NDMM, expert panelists consider the role of maintenance therapy following transplant.

Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1

July 13th 2022

Dr Nooka reviews the patient reported outcomes from the MajesTEC-1 trial in patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin Plus Lenalidomide/Dexamethasone Shows Efficacy, Safety in Newly Diagnosed Myeloma

July 8th 2022

The addition of belantamab mafodotin-blmf to lenalidomide and dexamethasone generated responses with acceptable safety in patients with newly diagnosed multiple myeloma who were ineligible to undergo autologous stem cell transplant.

Expanding Opportunities for Real-World Evidence in Oncology

July 7th 2022

Real-world evidence is finding an expanded role in oncology, prompting experts to rethink how data are gathered on the day-to-day usefulness of drugs for regulatory decisions.

Transplant-Eligible NDMM: Optimal Duration of Treatment

July 6th 2022

Expert perspectives on the optimal duration of treatment in patients with transplant-eligible newly diagnosed multiple myeloma.

Transplant-Eligible NDMM: Assessing Response to Therapy and Role of MRD Negativity

July 6th 2022

Comprehensive discussion on the assessment of response to frontline therapy for transplant-eligible multiple myeloma and the role of MRD negativity in assessing response.

More Novel Therapies Are on the Horizon in Multiple Myeloma

July 1st 2022

Ajai Chari, MD, discusses the evolving landscape and developing therapies within multiple myeloma.

Updated Progression-Free Survival and Depth of Response in IKEMA, a randomized phase 3 trial of Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) vs Kd in Relapsed Multiple Myeloma

July 1st 2022

Dr Elisabet Manasanch reviews updated data from the IKEMA study in patients with relapsed multiple myeloma.

FDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma

June 29th 2022

The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

Quadruplet Therapy in Transplant-Eligible NDMM: Implications of GRIFFIN and MASTER Studies

June 29th 2022

Shared insight on clinical trial results from both the GRIFFIN and MASTER trials, and the key role of frontline quadruplet regimens in transplant-eligible NDMM.

Evaluating Frontline Treatment Strategies in NDMM: The DETERMINATION Trial

June 29th 2022

Expert hematologist-oncologists open their discussion on NDMM management by reviewing frontline data from the recent DETERMINATION trial.

Teclistamab Elicits Survival Benefit vs Real-World Treatment in Multiple Myeloma

June 28th 2022

Teclistamab demonstrated superiority over physician’s choice of therapy for overall survival, progression-free survival, and time to next treatment in patients with relapsed/refractory multiple myeloma.

Cilta-cel Elicits an ORR of 100% in Multiple Myeloma After Early Relapse on Initial Therapy

June 24th 2022

The CAR T-cell therapy ciltacabtagene autoleucel generated a high response rate in patients with multiple myeloma who experienced early clinical relapse or failure to initial therapy.

CHMP Recommends Melphalan Flufenamide for Triple-Class Refractory Multiple Myeloma

June 23rd 2022

The European Medicines Agency's Committee for Medicinal Products for Human Use has unanimously recommended full marketing authorization approval of melphalan flufenamide for patients with triple-class refractory multiple myeloma.

Dr. Krishnan of the Effectiveness of Teclistamab in Relapsed/Refractory Multiple Myeloma

June 22nd 2022

Amrita Krishnan, MD, discusses the effectiveness of teclistamab in relapsed/refractory multiple myeloma.

Talquetamab Monotherapy Shows Early Promise in Relapsed/Refractory Multiple Myeloma

June 22nd 2022

Monique Minnema, MD, discusses the rationale of the MonumenTAL-1 trial examining talquetamab in multiple myeloma, the safety and efficacy reported thus far with the bispecific antibody, and next steps for further exploration.

Cilta-cel Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

June 20th 2022

A single infusion of the CAR T-cell therapy ciltacabtagene autoleucel produced deep and durable responses in patients with relapsed/refractory multiple myeloma with a manageable toxicity profile, according to long-term follow-up data of the phase 1b/2 CARTITUDE-1 trial.